Maxim Group Analysts Give Cytosorbents (CTSO) a $12.00 Price Target

Maxim Group set a $12.00 price objective on Cytosorbents (NASDAQ:CTSO) in a report released on Wednesday. The brokerage currently has a buy rating on the medical research company’s stock.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a buy rating and set a $14.00 price objective on shares of Cytosorbents in a research report on Wednesday. ValuEngine raised Cytosorbents from a sell rating to a hold rating in a research note on Tuesday, January 9th. Cowen set a $9.00 target price on Cytosorbents and gave the stock a buy rating in a research note on Thursday, March 8th. Finally, B. Riley reissued a buy rating and set a $11.25 target price on shares of Cytosorbents in a research note on Thursday, January 25th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $11.05.

CTSO traded up $0.15 on Wednesday, hitting $8.05. 157,566 shares of the stock were exchanged, compared to its average volume of 164,265. Cytosorbents has a 12 month low of $7.80 and a 12 month high of $8.05. The company has a quick ratio of 2.54, a current ratio of 6.16 and a debt-to-equity ratio of 0.68. The stock has a market capitalization of $240.25 million, a price-to-earnings ratio of -25.16 and a beta of -0.08.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Thursday, March 8th. The medical research company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.02). Cytosorbents had a negative return on equity of 88.39% and a negative net margin of 56.06%. The firm had revenue of $4.65 million for the quarter, compared to the consensus estimate of $4.56 million. sell-side analysts anticipate that Cytosorbents will post -0.47 EPS for the current fiscal year.

In other Cytosorbents news, CFO Kathleen P. Bloch sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $8.00, for a total transaction of $80,000.00. Following the completion of the transaction, the chief financial officer now owns 268,870 shares of the company’s stock, valued at $2,150,960. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Kathleen P. Bloch sold 11,176 shares of the business’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $8.25, for a total value of $92,202.00. Following the transaction, the chief financial officer now directly owns 261,246 shares of the company’s stock, valued at approximately $2,155,279.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,400 shares of company stock valued at $182,300. Insiders own 6.90% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in CTSO. Wells Fargo & Company MN increased its stake in shares of Cytosorbents by 182.3% in the fourth quarter. Wells Fargo & Company MN now owns 20,929 shares of the medical research company’s stock valued at $136,000 after buying an additional 13,515 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of Cytosorbents in the fourth quarter valued at approximately $146,000. Fortaleza Asset Management Inc. increased its stake in shares of Cytosorbents by 60.9% in the fourth quarter. Fortaleza Asset Management Inc. now owns 37,615 shares of the medical research company’s stock valued at $244,000 after buying an additional 14,240 shares during the period. Tibra Equities Europe Ltd acquired a new position in shares of Cytosorbents in the first quarter valued at approximately $362,000. Finally, BlueCrest Capital Management Ltd acquired a new position in shares of Cytosorbents in the fourth quarter valued at approximately $396,000. 10.53% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Analyst Recommendations for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Counterparty Achieves Market Capitalization of $38.37 Million
Counterparty Achieves Market Capitalization of $38.37 Million
Red Pulse Market Capitalization Achieves $66.99 Million
Red Pulse Market Capitalization Achieves $66.99 Million
Robeco Institutional Asset Management B.V. Has $6.73 Million Stake in Donaldson
Robeco Institutional Asset Management B.V. Has $6.73 Million Stake in Donaldson
Zoetis  Holdings Increased by Robeco Institutional Asset Management B.V.
Zoetis Holdings Increased by Robeco Institutional Asset Management B.V.
Lyell Wealth Management LP Raises Stake in Bank of America
Lyell Wealth Management LP Raises Stake in Bank of America
Numis Securities Lowers French Connection Group  to Add
Numis Securities Lowers French Connection Group to Add


Leave a Reply

© 2006-2018 Ticker Report. Google+.